Gene Silencing News and Research

RSS
New LNP compositions that improve systemic delivery of RNAi therapeutics discovered

New LNP compositions that improve systemic delivery of RNAi therapeutics discovered

Alnylam Pharmaceuticals presents data on multiple therapeutic programs at RNAi Symposium

Alnylam Pharmaceuticals presents data on multiple therapeutic programs at RNAi Symposium

Research reveals gene activation is linked to most aggressive type of brain cancer

Research reveals gene activation is linked to most aggressive type of brain cancer

Dicerna Pharmaceuticals and Kyowa Hakko Kirin sign research collaboration and license agreement

Dicerna Pharmaceuticals and Kyowa Hakko Kirin sign research collaboration and license agreement

Advances in development of “lipidoid” formulations for systemic delivery of RNAi therapeutics

Advances in development of “lipidoid” formulations for systemic delivery of RNAi therapeutics

Successful RNA interference to turn off multiple genes raises hope for new liver disease treatments

Successful RNA interference to turn off multiple genes raises hope for new liver disease treatments

E2F1 transcription factor inhibition reduces EGFR expression and invasive potential of melanoma cells

E2F1 transcription factor inhibition reduces EGFR expression and invasive potential of melanoma cells

Pistachios can decrease inflammation and cardiovascular disease

Pistachios can decrease inflammation and cardiovascular disease

New study reveals RNA may play a critical role in cancer treatment

New study reveals RNA may play a critical role in cancer treatment

ALS research collaboration receives philanthropic funding

ALS research collaboration receives philanthropic funding

RXi Pharmaceuticals announces financial results for the quarter ended September 30, 2009

RXi Pharmaceuticals announces financial results for the quarter ended September 30, 2009

Update on Alnylam Pharmaceuticals' RNAi pipeline, platform, and technology

Update on Alnylam Pharmaceuticals' RNAi pipeline, platform, and technology

Alnylam Pharmaceuticals presents new data related to its overall delivery research efforts

Alnylam Pharmaceuticals presents new data related to its overall delivery research efforts

Alnylam Pharmaceuticals presents new data from its transthyretin-mediated amyloidosis program

Alnylam Pharmaceuticals presents new data from its transthyretin-mediated amyloidosis program

Orion Genomics enters collaboration and license agreement with Novartis Pharma

Orion Genomics enters collaboration and license agreement with Novartis Pharma

RXi Pharmaceuticals presents new preclinical data from its advanced RNAi therapeutic platform

RXi Pharmaceuticals presents new preclinical data from its advanced RNAi therapeutic platform

Alnylam and Tekmira to collaborate on RNAi therapeutics

Alnylam and Tekmira to collaborate on RNAi therapeutics

Epigenetic alterations may serve as markers for chronic leukemia

Epigenetic alterations may serve as markers for chronic leukemia

Nanoparticle Trojan horse for ovarian cancer

Nanoparticle Trojan horse for ovarian cancer

MicroRNAs grease the cell's circadian clockwork

MicroRNAs grease the cell's circadian clockwork